A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals, CAI International and Peregrine Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Multi-Fineline Electronix Inc. (MFLX), AcelRx Pharmaceuticals Inc. (ACRX), CAI International Inc. (CAI) and Peregrine Pharmaceuticals Inc. (PPHM). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
To access our full PDF Research Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
MFLX Research Package: http://www.traders-choice.com/pdf?s=MFLX
ACRX Research Package: http://www.traders-choice.com/pdf?s=ACRX
CAI Research Package: http://www.traders-choice.com/pdf?s=CAI
PPHM Research Package: http://www.traders-choice.com/pdf?s=PPHM
============
Highlights from today's reports include:
On Wednesday, November 18, 2015, the NASDAQ Composite ended at 5,075.20, up 1.79%, the Dow Jones Industrial Average advanced 1.42%, to finish the day at 17,737.16, and the S&P 500 closed at 2,083.58, up 1.62%.
- Multi-Fineline Electronix Inc.'s stock advanced 0.60% to close Wednesday's session at USD 21.89. The share price vacillated between USD 21.48 and USD 22.11. The stock recorded a trading volume of 0.08 million shares, which was below its 50-day daily average volume of 0.14 million shares and 52-week average volume of 0.12 million shares. Over the last three days Multi-Fineline Electronix Inc.'s shares have advanced 3.50%, while in the past one week the stock has moved down 0.14%. However, in the last six months the stock has lost 14.69% but year to date the shares have picked up 94.92%. On a compounded total return basis, the company has returned 20.47% in the last three months. Further, the company is trading at a price to earnings ratio of 10.81x and a price to book ratio of 1.49x. Additionally, the stock is trading at a price to cash flow ratio of 7.04x and price to sales ratio of 0.59x. Moreover, the company is trading above its 50-day and 200-day moving averages of USD 19.47 and USD 19.83, respectively.
- AcelRx Pharmaceuticals Inc.'s stock slipped by 0.94% to close Wednesday's session at USD 5.25. The company's shares oscillated between USD 5.06 and USD 5.48. The stock recorded a trading volume of 0.58 million shares, which was above its 50-day daily average volume of 0.53 million shares and 52-week average volume of 0.57 million shares. Over the last one week AcelRx Pharmaceuticals Inc.'s shares have advanced 11.94% and in the past one month the stock has gained a momentum of 43.84%. In addition, over the last three months the stock has gained 23.53% while year to date the shares have shed 21.99%. The company has returned 67.20% in the past six months, on a compounded total return basis. Further, the stock is trading at a price to book ratio of 5.89x compared to historical PB ratio of 6.31x. Additionally, the stock is trading at a price to sales ratio of 13.26x. Moreover, the company is trading above its 50-day moving average of USD 3.96.
- CAI International Inc.'s stock declined 0.99% to close Wednesday's session at USD 10.98. The share price vacillated between USD 10.92 and USD 11.40. The stock recorded a trading volume of 0.09 million shares, which was below its 50-day daily average volume of 0.17 million shares and 52-week average volume of 0.11 million shares. Over the last three days CAI International Inc.'s shares have declined by 3.43% but in the past one month the stock has moved up 7.86%. Further, the company is trading at a price to earnings ratio of 4.19x and a price to book ratio of 0.58x. This compares to a historical PE ratio of 8.14x and historical PB ratio of 1.09x. Additionally, the stock is trading at a price to cash flow ratio of 1.87x and price to sales ratio of 1.17x. Moreover, the company is trading below its 50-day moving average of USD 11.07. CAI International Inc. has market capitalization of USD 222.04 million.
- Peregrine Pharmaceuticals Inc.'s stock edged higher by 0.88% to close Wednesday's session at USD 1.14. The company's shares oscillated between USD 1.12 and USD 1.14. The stock recorded a trading volume of 0.49 million shares, which was below its 50-day daily average volume of 1.02 million shares and below its 52-week average volume of 1.12 million shares. Over the last three days, Peregrine Pharmaceuticals Inc.'s shares have advanced 1.79% while in the past one week the stock has moved down 5.00%. Furthermore, over the last three months the stock has gained 1.79% but in the past six months the shares have shed 12.98%. Further, the stock is trading at a price to book ratio of 4.10x compared to a historical PB ratio of 4.29x. Additionally, the stock is trading at a price to sales ratio of 7.38x. Moreover, the stock is trading above its 50-day moving average of USD 1.10 but below its 200-day moving average of USD 1.22. Peregrine Pharmaceuticals Inc. has a market capitalization of USD 235.93 million.
--
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice
